In vitro and in vivo efficacy of a novel quinuclidinone derivative against breast cancer

Anticancer Research

Volumn 34, Issue 3, 2014, Pages 1367-1376

  Malki, Ahmed ^a,b   El Ashry, El Sayed ^c  

^a QATAR UNIVERSITY   (Qatar)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c Alexandria University Faculty Of Science   (Egypt)

Author keywords

Anticancer drugs; Bax; Breast cancer; Cell cycle; E Cadherin; P21; P53

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN D; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; QUINUCLIDINONE DERIVATIVE 2; UNCLASSIFIED DRUG; UVOMORULIN; METHYLNITROSOUREA; QUINUCLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER INHIBITION; CANCER THERAPY; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; FATTY LIVER; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY TUBULAR DILATION; LETHAL DOSE; LIVER ATROPHY; MCF 7 CELL LINE; NONHUMAN; PROTEIN DETERMINATION; RAT; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTICANCER DRUGS; BAX; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SCREENING; E-CADHERIN; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; METABOLISM; MITOCHONDRION; P21; PATHOLOGY; TUMOR CELL CULTURE; WISTAR RAT;

ANTICANCER DRUGS; BAX; BREAST CANCER; CELL CYCLE; E-CADHERIN; P21; P53;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; METHYLNITROSOUREA; MITOCHONDRIA; QUINUCLIDINES; RATS; RATS, WISTAR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899689932     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics: 2012. CA: Cancer J Clin 62(1): 10-29, 2012.
2. Benson JR and Jatoi I: The global breast cancer burden. Future Oncol 8: 697-702, 2012
3. Kanavos P: The rising burden of cancer in the developing world. Ann Oncol 17(Suppl 8): viii15-viii23, 2006.
4. Benner SE and Hong WK: Clinical chemoprevention: developing a cancer prevention strategy. J Nat Cancer Inst (Bethesda) 85: 1446-1447, 1993.
5. Malki A, Fathy L and El Ashry E: Novel Quinuclidinone derivatives induce apoptosis in lung cancer via sphingomyelinase pathways. Drug Res 63: 1-8, 2013.
6. Simstein R, Burow M and Parker A: Apoptosis, Chemoresistance and Breast Cancer: Insights from the MCF-7 Cell Model System. Exp Biol Med 228: 995-1003, 2003.
7. Fulda S, Galluzzi L and Kroemer G: Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464, 2010.
8. Ashkenazi A and Dixit VM: Death receptors signaling and modulation. Science 281: 1305-1308, 1998.
9. O'Connor L, Harris AW and Strasser A: CD95 (FAS/APO-1) and p53 signal apoptosis independently in diverse cell types. Cancer Res 60: 1217-1222, 2000.
10. Cory S and Adams JM: The Bcl2 family regulators of the cellular life-or-death switch. Nat Rev Cancer 9: 247-656, 2002.
11. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M and Schneiter S: Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. 111(3): 331-342, 2002.
12. Hartwell LH and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
13. Vousden KH and Lu X Live or let die: The cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
14. Burns TF, Bernhard EJ and El-Deiry WS: Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 20: 4601-4612, 2001.
15. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 645-656, 2002.
16. Riedl SJ and Shi YG: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907, 2004.
17. Lacroix M, Toillon RA and Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer 13: 293-325, 2006.
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J for Clin 61: 69-90, 2011.
19. McPherson K, Steel CM and Dixon JM: ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321: 624-628, 2000.
20. Chang S, Parker SL, Pham T, Buzdar AU and Hursting SD: Inflammatory breast carcinoma incidence and survival - The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992 Breast Can Res Treat 46: 40-7, 1997.
21. Korbakis D and Scorilas A: Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol. Tumour Biol 33: 865-875, 2012
22. Nagata S and Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
23. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM and Pagano M: Human cyclin nuclear protein essential for the G1-to- S phase transition. Mol Cell Biol 15: 2612-2624, 1995.
24. Mazumder S, Gong B and Almasan A: Cyclin E Induction by genotoxic stress leads to apoptosis of hematopoietic cells. Oncogene 19: 2828-2835, 2000.
25. Niculescu AB III, Chen X, Smeets M, Hengst L and Prives C: Effects of p21 (Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
26. Henley SA and Dick FA: The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Division 7: 10-14, 2012.
27. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991
28. Lee JM and Bernstein A: Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 14: 149-61, 1995.
29. Liebermann DA, Hoffman B and Steinman RA: Molecular controls of growth arrest and apoptosis:p53-dependent and independent pathways. Oncogene 11: 199-210, 1995.
30. Chiarugi V, Magnelli L, Cinelli M and Basi G: Apoptosis and the cell cycle. Cell Mol Biol Res 40(7-8): 603-612, 1994.
31. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
32. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
33. Harper J, Adami W and Guy R: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 75(4): 805-816, 1993.
34. Hardwick JM and Polster BM: Mitochondrial Outer Membrane Proteins Assist Bid in Bax-mediated Lipidic Pore Formation. Mol Cell 2002 10: 963-965, 2002.
35. Welsch CW: Host factors affecting the growth of carcinogen induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res 45: 3415-3443, 1985.
36. Russo J, Russo IH, Rogers AE, Van zweiten MJ and Gusterson B: Tumors of mammary gland. In Pathology of Tumors in Laboratory Animals. IARC Scientific Publications 1: 47-78, 1990.
37. Thompson HJ, Mc Ginley JN, Rothhammer K and Singh M: Rapid induction of mammary intra ductal proliferation, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrourea. Carcinogenesis 16: 2407-2411, 1995.
38. Clevers H: Wnt/β-Catenin signaling in development and disease. Cell 13: 469-480, 2006.
39. Khalil S, Tan GA, Gurl DD, Zhou XK and Howe LR: Activation status of Wnt/β-catenin signaling in normal and neoplastic breast tissurs: Relationship to her2/neu expression in human and mouse. PLOS 13: e3342, 2012.
40. Dakeng S, Duangmano S, Jiratchariyahul W, U-Pratya Y, Bogler O and Patmasriwat P: Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: Reduction of Wnt-associated proteins and reduced translocation of Galectin-3-mediated β-Catenin. J Cell Biochem 13: 49-60, 2012.
41. Preet R, Mohapatra P, Das D, Satapathy S, Choudhuri T, Wyatt MD et al: Lycopene synergistically enhances quinacrine actin to inhibit Wnt-TCF signaling in breast cancer cells through APC. Carcinogenesis 34(2): 277-286, 2012.
42. Peifer M and Polokis P: Wnt signaling in oncogensis and embryogenesis: a look outside the nucleus. Science 13: 1606-1609, 2000.